Respiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences and Neurosciences, Siena University Hospital, 53100, Siena, Italy.
Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy.
Intern Emerg Med. 2020 Oct;15(7):1247-1254. doi: 10.1007/s11739-020-02281-8. Epub 2020 Feb 20.
Chronic hypersensitivity pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from inhalation of different organic substances and chemical compounds determining an inflammatory and immunological response in sensitized individuals. KL-6, a human mucin protein expressed by type 2 pneumocytes, has been proposed as a prognostic biomarker of cHP. Assessment of usefulness KL-6 in ILD has been investigated primarily in Asiatic population. The aim of this study was to evaluate clinical utility of KL-6 in serum and bronchoalveolar lavage (BAL). In this study, we retrospectively analysed clinical, radiological and immunological data of a cohort of 42 patients affected by cHP: KL-6 concentrations were collected from serum and BAL. KL-6 clinical value was assessed through the analysis of association between KL-6 concentrations and clinical, functional, immunological and radiological features. KL-6 serum concentration results increased in 28/34 patients (82%). A positive direct correlation was observed between KL-6 concentrations in BAL and serum (r = 0.62, p < 0.05). In our study population we found that patients with extensive presence of ground glass opacities and centrilobular nodules at high-resolution computed tomography (HRCT) showed the highest concentrations of KL-6 in BAL and a predominantly CD3+ CD8+ BAL lymphocytosis. BAL lymphocytosis and KL-6 concentrations showed a direct correlation. BAL KL-6, a result of alveolar damage, caused in cHP by CD3+ CD8+ mediated flogosis and suggested by radiological evidence of ground-glass opacities and centrilobular nodules, can be considered a useful biomarker to assess, along with BAL cellular analysis and HRCT findings, disease activity.
慢性过敏性肺炎(cHP)是一种纤维化的间质性肺疾病(ILD),由吸入不同的有机物质和化合物引起,导致敏感个体发生炎症和免疫反应。KL-6 是一种由 2 型肺泡细胞表达的人类粘蛋白蛋白,已被提议作为 cHP 的预后生物标志物。KL-6 在ILD 中的有用性评估主要在亚洲人群中进行。本研究旨在评估 KL-6 在血清和支气管肺泡灌洗液(BAL)中的临床实用性。在这项研究中,我们回顾性分析了 42 例 cHP 患者的临床、放射学和免疫学数据:从血清和 BAL 中收集 KL-6 浓度。通过分析 KL-6 浓度与临床、功能、免疫和放射学特征之间的关联,评估 KL-6 的临床价值。结果显示,34 例患者中有 28 例(82%)血清 KL-6 浓度升高。BAL 和血清中 KL-6 浓度之间存在正直接相关性(r=0.62,p<0.05)。在我们的研究人群中,我们发现高分辨率计算机断层扫描(HRCT)显示广泛存在磨玻璃影和小叶中心结节的患者,BAL 和 BAL 中 CD3+CD8+淋巴细胞增多症中 KL-6 浓度最高。BAL 淋巴细胞增多症和 KL-6 浓度之间存在直接相关性。BAL KL-6 是由 CD3+CD8+介导的 flogosis 引起的肺泡损伤的结果,并且由磨玻璃影和小叶中心结节的放射学证据提示,可以被认为是一种有用的生物标志物,可与 BAL 细胞分析和 HRCT 结果一起评估疾病活动度。